Novel Estrogen Receptor ß (ERß) Drugs for the Treatment of Multiple Sclerosis (MS)

Tech ID: 32447 / UC Case 2018-285-0

Background

Multiple sclerosis (MS) is an autoimmune, demyelinating, and neurodegenerative disease of the central nervous system (CNS) with no known cause or cure. Currently available therapeutic agents approved for the treatment of multiple sclerosis (MS) reduce relapse rates, but do not reverse or prevent neurodegeneration nor initiate myelin repair. There is thus a great need for effective therapies against MS.

Brief Description

Prof. Seema K. Tiwari-Woodruff from the University of California, Riverside, Prof. John Katzellenbogen and colleagues from the University of Illinois have developed novel estrogen receptor β (ERβ) drugs for the treatment of MS. These novel MS drugs are specific for ERβ and have tremendous potential for the treatment of MS as well as other neurodegenerative diseases. In general, estrogens have anti-inflammatory and neuroprotective activities and clinically reduce the severity of MS and other neurodegenerative diseases. The compounds are more superior to other estrogenic drugs due to their specificity for ERβ and lack of undesirable effects such as feminization and increased risk of cancer.
2018-285

Fig 1: Therapeutic treatment with the UCR ERβ ligands began at peak disease (day 17) and was continued daily till day 36. ERβ ligands (blue, and orange) significantly attenuated clinical disease severity compared to vehicle treatment (red).

 

Applications

  • For the treatment of Multiple Sclerosis (MS) and other neurodegenerative diseases without undesirable side effects such as feminization and increased risk of cancer.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 2021/023012 07/29/2021 2018-285
 

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

estrogen receptor ß, neurodegenerative diseases, ERß, multiple sclerosis

Categorized As